期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 9, 页码 5814-5818出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00534-15
关键词
-
资金
- Agency for Innovation by Science and Technology (IWT, Belgium)
- European Commission through its SILVER project [HEALTH-F3-2010-260644]
- KU Leuven Geconcerteerde Onderzoeksactie [GOA 10/014]
- BELSPO IUAP consortium BELVIR (Belgium)
- German Center for Infection Research (DZIF) [TTU 01.803]
The novel enterovirus protease inhibitor (PI) SG85 effectively inhibits the in vitro replication of 14 rhinoviruses representative of species A and B (median 50% effective concentration, 0.04 mu M). A low-level SG85-resistant variant was selected that carried amino acid substitutions S127G and T143A in the 3C protease. Both substitutions are required for low-level resistance to SG85, as demonstrated by reverse genetics. Interestingly, there is no cross-resistance to SG85 and rupintrivir (another PI); a structural explanation is provided for this observation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据